The FDA has granted orphan-drug status to Omeros' experimental antibody drug OMS721 as a treatment for complement-mediated thrombotic microangiopathies, which can cause clotting in the body's organs. A Phase I trial is underway to determine the drug's safety and pharmacokinetics. Omeros plans to conduct a midstage trial early next year to assess the drug's efficacy in preventing complement-mediated thrombotic microangiopathies.

Related Summaries